Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Cipla
Argus Health
Cantor Fitzgerald
Covington
Fuji
US Army
Johnson and Johnson
McKinsey
Boehringer Ingelheim

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,149,532

« Back to Dashboard

Which drugs does patent 9,149,532 protect, and when does it expire?

Patent 9,149,532 protects SAVAYSA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-three countries.
Summary for Patent: 9,149,532
Title:Pharmaceutical composition
Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive. ##STR00001##
Inventor(s): Kojima; Masazumi (Shinagawa-ku, JP), Kuno; Yoshio (Shinagawa-ku, JP), Nakagami; Hiroaki (Shinagawa-ku, JP), Sagasaki; Shinji (Shimada, JP), Ishidoh; Koichi (Hiratsuka, JP), Sekiguchi; Gaku (Hiratsuka, JP)
Assignee: Daiichi Sanykyo Company, Limited (Tokyo, JP)
Application Number:13/968,776
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 9,149,532

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-002 Jan 8, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,149,532

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-087327Mar 29, 2007

Non-Orange Book US Patents Family Members for Patent 9,149,532

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,707,296 Pharmaceutical composition ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,149,532

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2009139917 ➤ Sign Up
Portugal 2140867 ➤ Sign Up
Philippines 12012500410 ➤ Sign Up
New Zealand 597109 ➤ Sign Up
New Zealand 579725 ➤ Sign Up
Malaysia 149356 ➤ Sign Up
Mexico 2009010474 ➤ Sign Up
Lithuania 2140867 ➤ Sign Up
South Korea 101424843 ➤ Sign Up
South Korea 20090122950 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Covington
US Army
Boehringer Ingelheim
Farmers Insurance
Moodys
Mallinckrodt
Deloitte
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot